Sacituzumab Tirumotecan Plus Pembrolizumab Meets Phase III Endpoint in First-Line PD-L1-Negative Non-Squamous NSCLC
Sacituzumab Tirumotecan Plus Pembrolizumab Meets Phase III Endpoint in First-Line PD-L1-Negative Non-Squamous NSCLC Kelun-Biotech has announced positive phase III results for sacituzumab tirumotecan…
Read the full articleYou might also wanna read
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy
Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Conditions : Recurrent or Metastatic Head and Neck Carcinoma Interventions : Drug: Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor
Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Conditions : Gastric Adenocarcinoma; Gastroesophageal Junction (GEJ) Adenocarcinoma; Gastro-esophageal Junction Adenocarcinoma Interventions
Real-World EV Plus Pembro Success Seen in Urothelial Cancer
A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in p
Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
Conditions : Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC; EGFR Mutation-negative and A
A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC
Conditions : NSCLC Interventions : Drug: SYS6010 Sponsors : Sichuan University Not yet recruiting
Comments
Sign in to join the conversation.
No comments yet. Be the first.